CLL EA9161
Study #EA9161A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Back To Clinical Trials
Covid-19 Alert: if you have cold or flu-like symptoms (fever, cough, difficulty breathing, body aches, or chills, headache, sore throat, or loss of taste or smell), you must call us at 515.282.2921 before coming into Mission Cancer + Blood, even if you have an appointment. Tell us about your symptoms before coming in – Thank you!